| P50 | author | Linnéa Bergenholm | Q88444495 |
| P2093 | author name string | T Collins | |
| | J Parkinson | |
| | M J Chappell | |
| | N D Evans | |
| | J Mettetal | |
| P2860 | cites work | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans | Q24608179 |
| | Mouse heart Na+ channels: primary structure and function of two isoforms and alternatively spliced variants | Q28504505 |
| | The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands | Q28603128 |
| | The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. | Q30488645 |
| | Parameter Identifiability of Fundamental Pharmacodynamic Models | Q30830719 |
| | A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data | Q30992286 |
| | PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data | Q31037653 |
| | Animal research: reporting in vivo experiments: the ARRIVE guidelines | Q34116755 |
| | The relevance of cellular to clinical electrophysiology in classifying antiarrhythmic actions | Q34534295 |
| | How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? | Q35036150 |
| | Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development | Q35095735 |
| | Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation. | Q35698299 |
| | THE RATIO BETWEEN THE HEART-WEIGHT AND BODY-WEIGHT IN VARIOUS ANIMALS. | Q36240881 |
| | The promiscuous nature of the cardiac sodium current | Q36731634 |
| | Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation | Q37369309 |
| | Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block | Q37396589 |
| | An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation | Q37784281 |
| | The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development | Q38093949 |
| | L-type CaV1.2 calcium channels: from in vitro findings to in vivo function. | Q38175138 |
| | The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation | Q38464750 |
| | On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex | Q38464799 |
| | Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously | Q38491261 |
| | Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human | Q39438124 |
| | Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical | Q39613654 |
| | Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system | Q39961684 |
| | The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. | Q41484309 |
| | Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. | Q42332476 |
| | Experimental design and analysis and their reporting: new guidance for publication in BJP. | Q42356330 |
| | Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment | Q42514265 |
| | Importance of species selection in arrythmogenic models of Q-T interval prolongation | Q42782038 |
| | Use of escin as a perforating agent on the IonWorks quattro automated electrophysiology platform | Q43777642 |
| | Duration of QRS complex in resting electrocardiogram is a predictor of sudden cardiac death in men. | Q44375576 |
| | Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs. | Q45962823 |
| | Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. | Q46348942 |
| | Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. | Q46916241 |
| | The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds | Q48153495 |
| | Predicting changes in cardiac myocyte contractility during early drug discovery with in vitro assays. | Q51073087 |
| | Voltage-gated Na+ channel transcript patterns in the mammalian heart are species-dependent. | Q51731090 |
| | Antiarrhythmic agents: modulated receptor applications. | Q51794509 |
| | Operational models of pharmacological agonism. | Q52699226 |
| | Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues | Q68339875 |
| | The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans | Q70046808 |
| | Comparison of intravenous and oral verapamil dosing | Q70509532 |
| | Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST) | Q72580560 |
| | Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding | Q73311345 |
| | Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment | Q84451696 |
| | Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing | Q86446569 |
| | Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism | Q93571513 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3268-3283 | |
| P577 | publication date | 2017-08-24 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Predicting QRS and PR interval prolongations in humans using nonclinical data | |
| P478 | volume | 174 | |